Solid Biosciences Inc.

Solid did not give quarterly revenue or EPS figures in this call, but it did say first-quarter financial results were filed on Form 10-Q and that cash was approximately $180 million at the end of Q1 2022. Management said the company reduced headcount by approximately 35% and expects the focused structure to extend its cash runway into Q2 2024. On SGT-001, the company said IGNITE DMD enrollment is concluded, patients will be dosed with material from the new transient-transfection process, and dosing is expected to resume in the first half of 2023. For SGT-003, the company is targeting an IND submission in early 2023 and clinical proof of concept in 2023.

Ilan Ganot framed the quarter as a strategic reset around two programs in Duchenne: continuing SGT-001 with a new transient-transfection manufacturing route and advancing SGT-003’s next-generation capsid toward the clinic. His tone was confident and pragmatic, emphasizing that the transition should have minimal impact on timelines for a potential BLA filing and that both programs have enough merit to justify continued investment. He also highlighted the organizational simplification, saying the company has focused operations, reduced headcount, and preserved runway to key clinical milestones.

No traditional CFO commentary or detailed financial tables were provided on the call, but management repeatedly cited cash of approximately $180 million at the end of Q1 2022 and a runway through Q2 2024. The company said the strategic reorganization reduced headcount by about 35% and that the streamlined structure is intended to support clinical progress on both programs. Management also said the new SGT-001 manufacturing approach is already in motion and that the company has engaged regulators on how to demonstrate comparability, likely through analytical methods and possibly in vivo dosing.

Analysts focused on whether the new SGT-003 capsid could support lower doses, whether microdystrophin had been tested in primates, and whether SGT-001 would require additional CMC/comparability work before a pivotal study. Management said the monkey work used luciferase rather than microdystrophin, but mouse data gave them confidence the platform is in the right range, with a stated goal of at least a twofold improvement versus AAV9. On SGT-001, management said comparability will need to be shown, likely through analytics and perhaps in vivo work, and said regulators have already been engaged on the transition. Later questions pushed on why both programs should be advanced rather than prioritize one; Ganot answered that both have convincing data and both deserve continued development at this stage.